Literature DB >> 16445911

Neuropilins in neoplasms: expression, regulation, and function.

Diane R Bielenberg1, Curtis A Pettaway, Seiji Takashima, Michael Klagsbrun.   

Abstract

Neuropilins (NRP) are membranous receptors capable of binding two disparate ligands, class 3 semaphorins (SEMA) and vascular endothelial growth factors (VEGF), and regulating two diverse systems, neuronal guidance and angiogenesis. The neuropilin genes, NRP1 and NRP2, share similar protein structure, but differ in their expression patterns, regulation, and ligand-binding specificities. NRPs vary in their expression patterns; for example, endothelial cells express both NRP1 and NRP2, lymphatic endothelial cells predominantly express NRP2, and epidermal cells predominantly express NRP1. NRP expression can be differentially regulated by transcription factors, e.g. prox-1 induces NRP2 while suppressing NRP1, or by growth factors, e.g. epidermal growth factor (EGF) induces NRP1 but not NRP2. Nearly all tumor cells express NRP1, NRP2, or both. Carcinomas express NRP1, whereas neuronal tumors and melanomas predominantly express NRP2. SEMAs play a role in neoplasms as angiogenesis inhibitors. For example, SEMA3F, which binds specifically to NRP2, inhibits tumor angiogenesis and metastasis. Metastatic tumor cells lose SEMA3F expression during progression. Therefore, SEMA3F may have therapeutic potential. This article focuses on the role of NRPs and SEMAs in tumor progression and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16445911     DOI: 10.1016/j.yexcr.2005.11.024

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  107 in total

1.  Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice.

Authors:  Daniela Bumbaca; Hong Xiang; C Andrew Boswell; Ruediger E Port; Shannon L Stainton; Eduardo E Mundo; Sheila Ulufatu; Anil Bagri; Frank-Peter Theil; Paul J Fielder; Leslie A Khawli; Ben-Quan Shen
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Authors:  Shom Goel; Andus Hon-Kit Wong; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

Review 3.  Regulation of immune cell responses by semaphorins and their receptors.

Authors:  Hyota Takamatsu; Tatsusada Okuno; Atsushi Kumanogoh
Journal:  Cell Mol Immunol       Date:  2010-02-01       Impact factor: 11.530

Review 4.  The neurovascular retina in retinopathy of prematurity.

Authors:  Anne B Fulton; Ronald M Hansen; Anne Moskowitz; James D Akula
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

5.  Paxillin controls endothelial cell migration and tumor angiogenesis by altering neuropilin 2 expression.

Authors:  Alexandra E German; Tadanori Mammoto; Elisabeth Jiang; Donald E Ingber; Akiko Mammoto
Journal:  J Cell Sci       Date:  2014-02-12       Impact factor: 5.285

6.  Inflammation and Lymphedema Are Exacerbated and Prolonged by Neuropilin 2 Deficiency.

Authors:  Patrick Mucka; Nicholas Levonyak; Elena Geretti; Bernadette M M Zwaans; Xiaoran Li; Irit Adini; Michael Klagsbrun; Rosalyn M Adam; Diane R Bielenberg
Journal:  Am J Pathol       Date:  2016-10-14       Impact factor: 4.307

7.  ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human glioma cells.

Authors:  Akio Shimizu; Akiko Mammoto; Joseph E Italiano; Elke Pravda; Andrew C Dudley; Donald E Ingber; Michael Klagsbrun
Journal:  J Biol Chem       Date:  2008-07-25       Impact factor: 5.157

8.  Tie2Cre-mediated inactivation of plexinD1 results in congenital heart, vascular and skeletal defects.

Authors:  Ying Zhang; Manvendra K Singh; Karl R Degenhardt; Min Min Lu; Jean Bennett; Yutaka Yoshida; Jonathan A Epstein
Journal:  Dev Biol       Date:  2008-10-17       Impact factor: 3.582

9.  Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma.

Authors:  Matija Snuderl; Ana Batista; Nathaniel D Kirkpatrick; Carmen Ruiz de Almodovar; Lars Riedemann; Elisa C Walsh; Rachel Anolik; Yuhui Huang; John D Martin; Walid Kamoun; Ellen Knevels; Thomas Schmidt; Christian T Farrar; Benjamin J Vakoc; Nishant Mohan; Euiheon Chung; Sylvie Roberge; Teresa Peterson; Carlos Bais; Boryana H Zhelyazkova; Stephen Yip; Martin Hasselblatt; Claudia Rossig; Elisabeth Niemeyer; Napoleone Ferrara; Michael Klagsbrun; Dan G Duda; Dai Fukumura; Lei Xu; Peter Carmeliet; Rakesh K Jain
Journal:  Cell       Date:  2013-02-28       Impact factor: 41.582

10.  Combined inhibition of vascular endothelial growth factor receptor signaling with temozolomide enhances cytotoxicity against human glioblastoma cells via downregulation of Neuropilin-1.

Authors:  Jungwhoi Lee; Eunsoo Kim; Seung-Wook Ryu; Chulhee Choi; Kyungsun Choi
Journal:  J Neurooncol       Date:  2016-03-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.